Alector provides 2021 corporate portfolio update

South san francisco, calif., jan. 07, 2021 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned clinical and research priorities for 2021.

ALEC Ratings Summary

ALEC Quant Ranking